From a prostate cancer combo that uses your tumor's own broken DNA-repair against it, to the first drug ever to succeed in a rare autoimmune disease called IgG4-related disease — Part 2 of our weekly biomedicine recap covers three more major readouts from the week of May 30 – June 5, 2026. In Part 2 we cover:

4. Pfizer — Talazoparib plus enzalutamide for metastatic castration-sensitive prostate cancer with DNA-repair mutations (Phase 3)

5. Zenas BioPharma — Obexelimab for IgG4-related disease (Phase 3)

6. Karyopharm Therapeutics — Selinexor plus ruxolitinib for myelofibrosis (Phase 3)

The IgG4-RD result may be the most quietly historic of the week: IgG4-related disease is a rare autoimmune condition where misbehaving B cells form fibrotic masses in organs throughout the body, and there has never been an approved therapy — patients rely on steroids long-term. Obexelimab, a clever 'bifunctional' antibody that calms B cells without killing them, cut the risk of disease flare by 56% in a 52-week Phase 3 trial — the first positive Phase 3 ever in this disease, published in the New England Journal of Medicine. We explain what makes the antibody design unusual and why a positive trial here could change rare-disease drug development more broadly.

Catch Part 1 if you missed it. Subscribe at TrialBreaks.com

#oncology #prostatecancer #PARPinhibitor #autoimmune #IgG4 #rheumatology #rarediseases #myelofibrosis #hematology #targetedtherapy #precisionmedicine #biomedicine #clinicaltrials #science

The biggest week in cancer research of 2026 dropped at the ASCO meeting in Chicago, and one drug stole the show: a new RAS-blocking pill that nearly doubled survival in metastatic pancreatic cancer, one of the deadliest diseases in medicine. In Part 1 we cover:

1. Revolution Medicines — Daraxonrasib for metastatic pancreatic cancer (Phase 3)
2. Summit Therapeutics and Akeso — Ivonescimab for first-line squamous non-small cell lung cancer (Phase 3)
3. Eli Lilly — Selpercatinib for adjuvant RET fusion-positive non-small cell lung cancer (Phase 3)
Daraxonrasib targets RAS, the 'on switch' that drives roughly a third of all cancers and almost every pancreatic tumor. Unlike earlier RAS drugs that hit only one specific mutation, daraxonrasib blocks the active form of multiple RAS variants at once — and the result was a near-doubling of median overallsurvival from 6.6 months to 13.2 months in patients who had already failed first-line chemo. Doctors at the ASCO Plenary called the data 'transformative' and gave a standing ovation. We break down the science, explain why pancreatic cancer has been so untreatable, and walk through what RAS-ON inhibitors could mean for other tumors in the years ahead.
Part 2 drops Thursday morning. Subscribe at TrialBreaks.com
#oncology #pancreaticcancer #lungcancer #precisionmedicine #RAS #immunotherapy #bispecificantibody #PD1 #targetedtherapy #ASCO2026 #biomedicine #clinicaltrials #science

In Part 2 we cover the remaining clinical trial readouts from the week of May 23–29, 2026 — a Phase 2 atopic dermatitis breakthrough and a Phase 3 multiple sclerosis convenience win.
4. Apogee Therapeutics — Zumilokibart for Moderate-to-Severe Atopic Dermatitis (Phase 2)
5. TG Therapeutics — BRIUMVI (ublituximab-xiiy) for Relapsing Forms of Multiple Sclerosis (Phase 3 ENHANCE)
Apogee Therapeutics delivered a strong Phase 2 result in moderate-to-severe atopic dermatitis — 65.9% of mid-dose patients achieved a 75% reduction in disease severity at 16 weeks, compared with 23.4% on placebo. TG Therapeuticsshowed that a single Day-1 infusion of BRIUMVI gives the same drug exposure as the current two-dose initiation, simplifying multiple sclerosis treatment for thousands of patients.
Catch Part 1 if you missed it. Subscribe at TrialBreaks.com
#dermatology #atopicdermatitis #multiplesclerosis #neurology #biomedicine #clinicaltrials #science #medicalresearch